Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 63

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 63
---
 may be implemented in the future. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future product candidates that we develop.

We are subject to environmental laws and regulations that govern the use, storage, handling and disposal of hazardous materials and other waste products.

We are subject to environmental
laws and regulations governing the use, storage, handling and disposal of hazardous materials and other waste products. We have health
and safety policies and procedures in place to assess the risks associated with use of hazardous materials, and the assessment includes
information for employees on how the substances should be used to avoid contamination of the environment and inadvertent exposure to themselves
and their colleagues. Despite our precautions for handling and disposing of these materials, we cannot eliminate the risk of accidental
contamination or injury. In the event of a hazardous waste spill or other accident, we could be liable for damages, penalties or other
forms of censure. If we fail to comply with any laws or regulations, or if an accident occurs, we may have to pay significant penalties
and may be held liable for any damages that result. This liability could exceed our financial resources and could harm our reputation.
We may also have to incur significant additional costs to comply with current or future environmental laws and regulations. Our failure
to comply with any government regulation applicable to our laboratory and the materials used in our laboratory may adversely affect our
ability to develop, produce, market or partner any products we may commercialize or develop.

| 33 |

Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.

We are exposed to the risk
of employee fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by such
parties could include intentional failures to comply with applicable regulations, provide accurate information to regulatory authorities,
comply with manufacturing standards, comply with healthcare fraud and abuse laws and regulations, report financial information or data
accurately, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry
are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws
and regulations may restrict or prohibit a